During the project timeline from March 1st, 2024, to August 31th, 2025, our team has engaged in making progress toward the project goals.
- The consortium has made significant progress in understanding post-COVID-19 neurological sequelae through the steady enrolment of participants in two independent Italian and German cohorts. Key achievements include the recruitment of over 300 individuals, with a focus on diverse symptomatology, particularly fatigue and cognitive impairments. Biological samples for high-dimensional analyses have been successfully collected, including blood and cerebrospinal fluid, to explore potential neurological risks and genetic vulnerabilities. Epidemiological studies are also ongoing and so far highlighted a threefold increased risk of severe neurological complications following COVID-19, with ongoing analyses set to enhance our understanding of these conditions. Collaborative efforts to harmonize methodologies between cohorts are also underway, ensuring robust data integration for future research.
- The study has achieved significant milestones in understanding post‑COVID‑19 with neurological sequelae through comprehensive multi-omics profiling and patient-specific disease trajectory identification. We generated single-cell multiOMIC profiles for almost 300 individuals, revealing potential blood biomarkers linked to post-COVID syndrome. High-dimensional flow cytometry and proteomic analyses were conducted, providing insights into neuroinflammatory mediators. Our teams have prioritized patients for induced pluripotent stem cells (iPSCs) reprogramming, useful for the generation of in vitro brain organoid models of the disease. Research on host viral restriction factors is underway, with genome-wide screens prepared using human pluripotent stem cell-derived neurons. Overall, the project is paving the way for deeper insights into the cellular and molecular mechanisms of NeuroCOVID.
- The project has made significant contributions in defining patient profiles through single-cell analyses, including transcriptional disease fingerprints for immune cells in patients with post‑COVID‑19 associated neurological symptoms. We also focused on developing causal artificial intelligence (AI) methods for mapping regulatory networks, enabling predictive modeling of disease states. The project aims to integrate diverse data sources for comprehensive analysis and validation in the coming months.
- During this reporting period, significant progress has been made concerning societal and ethical aspects of neurological post‑COVID‑19. We completed a meta-review of literature and social media on NEUROCOV advocacy by April 2024, gathering qualitative data from healthcare professionals, researchers, and patient organizations. We also investigated the challenges related to data sharing within COVID-19 health data infrastructures in Europe, with findings leading to three publications addressing the European Health Data Space. Ongoing analyses of data valorisation practices and AI model access challenges are also in progress. Overall, the project is successfully addressing the ethical, legal, and social implications of NEUROCOV research.
